ArticleJACC. Advances2026
Prevalence and Prognostic Implications of Atherosclerotic Coronary Artery Disease in Type 2 Myocardial Infarction.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 myocardial infarction (MI) (T2MI) is common and associated with adverse outcomes.
objectivesThe objective of the study was to evaluate the prevalence of coronary artery disease (CAD) in patients with T2MI and myocardial injury and its impact on outcomes.
methodsObservational U.S. cohort study of emergency department patients undergoing high-sensitivity cardiac troponin T measurement. Cases with >1 high-sensitivity cardiac troponin T increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. CAD was defined as a prior CAD, MI, or coronary revascularization or newly diagnosed CAD during index hospitalization. Two-year major adverse cardiovascular outcomes including all-cause, cardiovascular, and noncardiovascular death, acute MI, heart failure hospitalization, and coronary revascularization were compared between patients with T2MI or myocardial injury and CAD vs type 1 MI (T1MI).
resultsAmong 858 patients, 64 (7.5%) had T1MI, 91 (11%) had T2MI, and 703 (82%) had myocardial injury. Patients with T2MI and CAD (n = 31; 34% of T2MI) had higher major adverse cardiovascular outcomes than T1MI (65% vs 39%; adjusted HR [aHR]: 1.95; 95% CI: 1.2-3.6), driven by higher all-cause death (52% vs 20%; aHR: 2.2; 95% CI: 1.0-4.5), noncardiovascular death (26% vs 5%; aHR: 5.04; 95% CI: 1.3-19.3), acute MI (13% vs 2%; aHR: 9.2; 95% CI: 1.01-84.2), and heart failure hospitalization (32% vs 8%; aHR: 4.6; 95% CI: 1.6-13.7). Patients with myocardial injury and CAD (n = 245) demonstrated similar trends, although differences were not statistically significant after adjustment.
conclusionsCAD is common among patients with T2MI and myocardial injury and is associated with poor long-term outcomes. Its presence may facilitate risk-stratification and represent a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.